Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
doi: 10.1002/oby.22726 24 le RouxCWAstrupAFujiokaKGreenwayFLauDCWVan GaalLet al
This shift is reshaping market dynamics, with evolving regulatory oversight on Ozempic alternatives, emerging price competition across brands, and expanding investment opportunities in Indias pharmaceutical and biopharma manufacturing ecosystem
Analysts predict continued double-digit growth for the GLP-1/metabolic disease market, driven by global obesity trends and more indications
More news resources FDA Medwatch Drug Alerts Daily MedNews News for Health Professionals New Drug Approvals New Drug Applications Drug Shortages Clinical Trial Results Generic Drug Approvals Drugs.com Podcast Subscribe to our newsletter Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Become a member today to get access
They will also need to determine whether the apparent benefit is unique to GLP-1 receptor agonists or reflects a broader effect of improved metabolic control
US$ 26.31
US$ 26.54
US$ 27.92
US$ 21.28
US$ 26.75
